镰状细胞贫血中的胎儿血红蛋白:阿拉伯-印度单倍型与新型治疗药物
本文综述镰状细胞贫血中胎儿血红蛋白(HbF)调控的遗传基础,聚焦沙特阿拉伯患者。阿拉伯-印度单倍型患者HbF水平约为其他单倍型近两倍,贝宁单倍型沙特患者HbF为非洲患者近两倍但原因未明。羟基脲仍是FDA唯一批准诱导HbF的药物,10%–20%成人反应甚微,本文并讨论新型HbF诱导药物。
要点
- 阿拉伯-印度单倍型患者HbF水平较其他单倍型高近两倍。
- 贝宁单倍型沙特患者HbF约为非洲患者两倍,原因未明。
- 羟基脲为FDA唯一批准诱导HbF药物,10%–20%成人反应甚微。
核心结论
- 阿拉伯-印度单倍型相关高HbF位点需功能验证,贝宁单倍型沙特与非洲患者HbF差异原因未明。
- 羟基脲仍是FDA唯一批准用于镰状细胞病诱导HbF的药物,部分成人反应甚微。
研究设计与样本
- 综述,聚焦沙特阿拉伯镰状细胞贫血,总结HbF调控遗传基础并讨论新型HbF诱导药物。
主要发现
- 沙特与印度阿拉伯-印度单倍型患者HbF水平较非洲裔患者其他任何单倍型高近两倍。
- 贝宁单倍型沙特患者HbF水平几乎为携带该单倍型非洲患者的两倍,该差异未获解释。
- 接受羟基脲治疗的患者多数HbF升高并有一些临床改善,但10%–20%成人对该药反应甚微。
局限性
- 阿拉伯-印度单倍型中与高HbF相关的位点需功能确认。
- 贝宁单倍型沙特与非洲患者HbF差异未获解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fetal hemoglobin (HbF) has well-known tempering effects on the symptoms of sickle cell disease and its levels vary among patients with different haplotypes of the sickle hemoglobin gene. Compared with sickle cell anemia haplotypes found in patients of African descent, HbF levels in Saudi and Indian patients with the Arab-Indian (AI) haplotype exceed that in any other haplotype by nearly twofold. Genetic association studies have identified some loci associated with high HbF in the AI haplotype but these observations require functional confirmation. Saudi patients with the Benin haplotype have HbF levels almost twice as high as African patients with this haplotype but this difference is unexplained. Hydroxyurea is still the only FDA approved drug for HbF induction in sickle cell disease. While most patients treated with hydroxyurea have an increase in HbF and some clinical improvement, 10 to 20% of adults show little response to this agent. We review the genetic basis of HbF regulation focusing on sickle cell anemia in Saudi Arabia and discuss new drugs that can induce increased levels of HbF.
引用
- Habara AH, Shaikho EM, Steinberg MH, et al. Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents. Am J Hematol. 2017. PMID: 28736939. doi:10.1002/ajh.24872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。